Adam B. Weiner: SBRT and ADT for oligometastatic prostate cancer

Adam B. Weiner, Faculty at Cedars-Sinai Medical Center, shared an article by Giulia Marvaso, et al. on X:

“SBRT + ADT for oligometastatic prostate cancer.

RADIOSA trial – The Lancet Oncology.

Six months of ADT prolonged time to clinical progression from 15 to 32 months.”

Adam B. Weiner: SBRT and ADT for oligometastatic prostate cancer

Authors: Giulia Marvaso, et al.

Adam B. Weiner: SBRT and ADT for oligometastatic prostate cancer

Charles Jiang, Assistant Professor of Internal Medicine at UT Southwestern Medical Center, reshared the post on X, adding:

“Excellent result!

Personally would love to see more data using short term Arpi (with and without ADT) in psma pet area.”

Science

OncoDaily